{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:45:08Z","timestamp":1792457108546,"version":"4.5.0"},"reference-count":189,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.berh.2025.102106","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:04:40Z","timestamp":1759341880000},"page":"102106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Contemporary approaches to the management of rheumatoid arthritis: precision and progress"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8973-323X","authenticated-orcid":false,"given":"Tania","family":"Gudu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Oztas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3899\/jrheum.101133","article-title":"Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study","volume":"38","author":"Myasoedova","year":"2011","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2025.102106_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.berh.2014.10.016","article-title":"Seronegative rheumatoid arthritis: pathogenetic and therapeutic aspects","volume":"28","author":"Pratt","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000993","article-title":"Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift","volume":"5","author":"Chatzidionysiou","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2025.102106_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102405","article-title":"Precision medicine and management of rheumatoid arthritis","volume":"110","author":"Aletaha","year":"2020","journal-title":"J Autoimmun"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.1780301102","article-title":"The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis","volume":"30","author":"Gregersen","year":"1987","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B","article-title":"Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins","volume":"43","author":"MacGregor","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2025.102106_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.38273","article-title":"Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis","volume":"66","author":"de Hair","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis","volume":"233","author":"Bartok","year":"2010","journal-title":"Immunol Rev"},{"issue":"7","key":"10.1016\/j.berh.2025.102106_bib10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2025.102106_bib12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2025.102106_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11926-023-01116-7","article-title":"Oral versus subcutaneous methotrexate in immune-mediated inflammatory disorders: an update of the current literature","volume":"25","author":"Vermeer","year":"2023","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib14","first-page":"1","article-title":"EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update","volume":"84","author":"R\u00fcegg","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2025.102106_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/rheumatology\/keh088","article-title":"Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review","volume":"43","author":"Whittle","year":"2003","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ard-2023-224270","article-title":"Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?","volume":"83","author":"van Ouwerkerk","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2025.102106_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"10.1016\/j.berh.2025.102106_bib18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.berh.2025.102106_bib19","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.semarthrit.2014.11.003","article-title":"Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions","volume":"44","author":"Abasolo","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2025.102106_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00003495-198600321-00010","article-title":"Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine","volume":"32","author":"Farr","year":"1986","journal-title":"Drugs"},{"issue":"10061","key":"10.1016\/j.berh.2025.102106_bib22","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2025.102106_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/rheumatology\/key207","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis: executive summary","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/ar3537","article-title":"Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis","volume":"13","author":"Guyot","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.berh.2025.102106_bib26","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.berh.2025.102106_bib27","first-page":"A60","article-title":"Abatacept sc versus adalimumab on background methotrexate in RA: one year results from the AMPLE study","volume":"72","author":"Schiff","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib28","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2025.102106_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152517","article-title":"Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease: national multicentre study of 397 patients","volume":"68","author":"L\u00f3pez-Maraver","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib31","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.semarthrit.2017.03.024","article-title":"Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis","volume":"47","author":"Cappelli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2025.102106_bib33","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/rheumatology\/keab248","article-title":"Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020","volume":"61","author":"Norris-Grey","year":"2022","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib35","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002726","article-title":"Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"8","author":"Fragoulis","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2025.102106_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr2.11681","article-title":"COVID-19 vaccination before initiating rituximab treatment induces strong serological response in autoimmune rheumatic disease, reducing post-pandemic concerns about the impact of rituximab","volume":"6","author":"Ammitzb\u00f8ll","year":"2024","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.semarthrit.2011.08.008","article-title":"Biological agents in the management of Felty's syndrome: a systematic review","volume":"41","author":"Narv\u00e1ez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"9865","key":"10.1016\/j.berh.2025.102106_bib41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/rheumatology\/keae109","article-title":"Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in patients with rheumatoid arthritis in real-world practice: a prospective observational study","volume":"64","author":"Cho","year":"2025","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib44","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/kex489","article-title":"Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004291","article-title":"PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs","volume":"10","author":"van de Laar","year":"2024","journal-title":"RMD Open"},{"issue":"10139","key":"10.1016\/j.berh.2025.102106_bib46","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib47","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2025.102106_bib48","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib49","first-page":"991","article-title":"Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience","volume":"42","author":"La Barbera","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib50","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib51","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib52","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/rheumatology\/kead543","article-title":"Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"63","author":"Hayashi","year":"2024","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib53","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.42415","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/mr\/roac119","article-title":"Efficacy and safety of the anti-TNF multivalent NANOBODY\u00ae compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 52-week result of a Phase II\/III study (OHZORA trial)","volume":"33","author":"Tanaka","year":"2022","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2025.102106_bib55","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06073093. Accessed August 28, 2025."},{"issue":"9","key":"10.1016\/j.berh.2025.102106_bib56","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","article-title":"Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study","volume":"73","author":"Genovese","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2025.102106_bib57","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus placebo or adalimumab in rheumatoid arthritis","volume":"387","author":"Smolen","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2025.102106_bib58","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/annrheumdis-2020-eular.5465","article-title":"Fri0114 efficacy of levilimab, novel monoclonal anti-IL-6 receptor antibody, in combination with methotrexate in patients with rheumatoid arthritis: 1-year results of phase 2 Aurora study","volume":"79","author":"Mazurov","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102106_bib59","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: a phase Ia randomized placebo-controlled study","volume":"13","author":"Leng","year":"2022","journal-title":"Front Immuno"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib60","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/eji.1830211039","article-title":"Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha","volume":"21","author":"Haworth","year":"1991","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib61","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2016-210624","article-title":"A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/art.40323","article-title":"A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.berh.2025.102106_bib64","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/ard-2023-224449","article-title":"Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)","volume":"82","author":"Taylor","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"10.1016\/j.berh.2025.102106_bib65","volume":"75","author":"Wang","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib66","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/rheumatology\/keab699","article-title":"SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study","volume":"61","author":"Li","year":"2022","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2025.102106_bib67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/annrheumdis-2024-eular.1536","article-title":"OP0036 efficacy, safety, and pharmacokinetics of ANTI-CD40 antibody abiprubart (KPL-404) in patients with rheumatoid arthritis: a phase 2, randomized, placebo-controlled 12-WEEK-TREATMENT proof-of-concept study","volume":"83","author":"Jenkins","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"489","key":"10.1016\/j.berh.2025.102106_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar6584","article-title":"A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity","volume":"11","author":"Karnell","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib69","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/acr2.11487","volume":"4","author":"Abuqayyas","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2025.102106_bib70","first-page":"395","article-title":"A review of the Bruton tyrosine kinase inhibitors in B-cell malignancies","volume":"12","author":"Moore","year":"2021","journal-title":"J Adv Pract Oncol"},{"issue":"9","key":"10.1016\/j.berh.2025.102106_bib71","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib72","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40744-019-00182-7","article-title":"Spebrutinib (CC-292) affects markers of B cell activation, chemotaxis, and osteoclasts in patients with rheumatoid arthritis: results from a mechanistic study","volume":"7","author":"Schafer","year":"2020","journal-title":"Rheumatol Therapy"},{"issue":"8","key":"10.1016\/j.berh.2025.102106_bib73","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/ard-2022-223759","article-title":"Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial","volume":"82","author":"Takeuchi","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jnnp-2022-328799","article-title":"Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis","volume":"94","author":"Montalban","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib75","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard-2024-226385","article-title":"Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial","volume":"84","author":"Liu","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2025.102106_bib76","first-page":"200","article-title":"LB0001 head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: interim results from a phase IIa study","volume":"82","author":"Zeng","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102106_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106257","article-title":"Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjects","volume":"176","author":"Li","year":"2022","journal-title":"Eur J Pharmaceut Sci"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib78","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2025.102106_bib79","series-title":"2013 ACR\/ARHP annual meeting, San Diego, CA","article-title":"A randomized, dose-ranging, placebo-controlled, 84-day study of INCB039110, a selective Janus kinase-1 inhibitor, in patients with active rheumatoid arthritis","author":"Luchi","year":"2013"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-021-02468-0","article-title":"A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis","volume":"23","author":"Weisel","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"20","key":"10.1016\/j.berh.2025.102106_bib82","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-006-0542-y","article-title":"Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study","volume":"17","author":"Hara","year":"2007","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib86","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"7","key":"10.1016\/j.berh.2025.102106_bib87","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/10480","article-title":"Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis","volume":"5","author":"Taniguchi","year":"1999","journal-title":"Nat med"},{"issue":"3","key":"10.1016\/j.berh.2025.102106_bib88","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/rheumatology\/keae357","article-title":"A double-blind, placebo-controlled, randomized multiple dose phase 1b trial of a CDK4\/6 inhibitor, TCK-276, in patients with active rheumatoid arthritis","volume":"64","author":"Tasaki","year":"2025","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib89","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib90","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/key312","article-title":"Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis","volume":"58","author":"Khatri","year":"2019","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.berh.2025.102106_bib91","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1016\/S2665-9913(24)00199-1","article-title":"Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial","volume":"6","author":"Zhang","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2025.102106_bib92","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1136\/annrheumdis-2022-222228","article-title":"Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and\/or anti-TNF\u03b1 therapy: a placebo-controlled phase II study","volume":"81","author":"Daien","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib93","first-page":"65","article-title":"Novel gene therapy for rheumatoid arthritis with single local injection: adeno-associated virus-mediated delivery of A20\/TNFAIP3","volume":"9","author":"Zhang","year":"2022","journal-title":"Mil Med Res"},{"issue":"8","key":"10.1016\/j.berh.2025.102106_bib94","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2025.102106_bib95","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","article-title":"Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis","volume":"35","author":"Li","year":"2025","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib96","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2025.102106_bib97","first-page":"1","article-title":"WHO scientific group on the burden of musculoskeletal conditions at the start of the new millennium. The burden of musculoskeletal conditions at the start of the new millennium","volume":"919","year":"2003","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib98","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","article-title":"Transforming clinical trials in rheumatology: towards patient-centric precision medicine","volume":"16","author":"Pitzalis","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101742","article-title":"Precision medicine in rheumatoid arthritis","volume":"36","author":"Bhamidipati","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13317-021-00152-6","article-title":"Potential clinical biomarkers in rheumatoid arthritis with an omic approach","volume":"12","author":"Puentes-Osorio","year":"2021","journal-title":"Auto Immun Highlights"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/00045632241285843","article-title":"Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: a comprehensive review","volume":"62","author":"Sahin","year":"2025","journal-title":"Ann Clin Biochem"},{"issue":"9","key":"10.1016\/j.berh.2025.102106_bib102","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/cells13090743","article-title":"Clinical phenotypes, serological biomarkers, and synovial features defining seropositive and seronegative rheumatoid arthritis: a literature review","volume":"13","author":"Perera","year":"2024","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.berh.2025.102106_bib103","doi-asserted-by":"crossref","first-page":"9534","DOI":"10.3390\/ijms22179534","article-title":"Current status of the search for biomarkers for optimal therapeutic drug selection for patients with rheumatoid arthritis","volume":"22","author":"Tsuchiya","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.berh.2025.102106_bib104","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib105","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib106","first-page":"991","article-title":"Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs","volume":"29","author":"Narvaez","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000742","article-title":"Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib","volume":"5","author":"Bird","year":"2019","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib108","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12891-021-04248-y","article-title":"Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy","volume":"22","author":"Juli\u00e0","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.55563\/clinexprheumatol\/g8xqxr","article-title":"Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept","volume":"39","author":"Kumar","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2025.102106_bib110","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3899\/jrheum.080770","article-title":"Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States","volume":"36","author":"Sokka","year":"2009","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib111","doi-asserted-by":"crossref","DOI":"10.1186\/ar4469","article-title":"Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year","volume":"16","author":"Kay","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib112","first-page":"814","article-title":"Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients","volume":"26","author":"Keenan","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib113","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/ard-2022-222784","article-title":"Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update","volume":"82","author":"Aletaha","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib114","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","article-title":"Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib115","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/acr.22765","article-title":"Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis","volume":"68","author":"Wang","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib116","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0913-x","article-title":"Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study","volume":"18","author":"Bay-Jensen","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.berh.2025.102106_bib117","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/14397595.2019.1621026","article-title":"Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: a post hoc analysis of the SURPRISE study","volume":"30","author":"Kato","year":"2020","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib118","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13075-022-02955-y","article-title":"The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry","volume":"24","author":"Padula","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/diagnostics12010182","article-title":"High sensitivity C reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or Jak inhibitors: a clinical and ultrasonographic study","volume":"12","author":"Frade-Sosa","year":"2022","journal-title":"Diagnostics"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib120","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/ard.2007.073825","article-title":"Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors","volume":"67","author":"J\u00f8rgensen","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2025.102106_bib121","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/rheumatology\/keu488","article-title":"Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab","volume":"54","author":"Wright","year":"2015","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.berh.2025.102106_bib122","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3899\/jrheum.121389","article-title":"Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis","volume":"40","author":"Shimamoto","year":"2013","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib123","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/14397595.2013.854079","article-title":"Drug free REmission\/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) study","volume":"24","author":"Nishimoto","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib124","first-page":"2069","article-title":"Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies","volume":"24","author":"Us\u00f3n","year":"1997","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib125","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/1756-185X.13921","article-title":"Diagnostic accuracy of 14-3-3 \u03b7 protein in rheumatoid arthritis: a meta-analysis","volume":"23","author":"Wang","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib126","doi-asserted-by":"crossref","DOI":"10.1186\/ar4547","article-title":"14-3-3\u03b7 is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage","volume":"16","author":"Maksymowych","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib127","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13075-015-0799-7","article-title":"Serum 14-3-3\u03b7 level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab","volume":"17","author":"Hirata","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/rheumatology\/keg037","article-title":"Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis","volume":"42","author":"Green","year":"2003","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib129","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/rheumatology\/38.11.1081","article-title":"Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis","volume":"38","author":"Posthumus","year":"1999","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2025.102106_bib130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.berh.2019.01.006","article-title":"MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis","volume":"32","author":"Lerner","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2025.102106_bib131","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1182\/blood-2002-03-0671","article-title":"Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis","volume":"100","author":"Ponchel","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib132","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.38941","article-title":"CD8+ T cell profiles in patients with rheumatoid arthritis and their relationship to disease activity","volume":"67","author":"Carvalheiro","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib133","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/rheumatology\/kel089","article-title":"Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood","volume":"45","author":"Lawson","year":"2006","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2025.102106_bib134","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/ard.2009.117341","article-title":"Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?","volume":"69","author":"Saleem","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib135","first-page":"126","article-title":"Can biomarkers predict successful tapering of conventional disease-modifying therapy in rheumatoid arthritis patients in stable remission?","volume":"41","author":"Gul","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib136","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/rheumatology\/keac715","article-title":"Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis","volume":"62","author":"Meznerics","year":"2023","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib137","doi-asserted-by":"crossref","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.berh.2025.102106_bib138","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"Lliso-Ribera","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10271","key":"10.1016\/j.berh.2025.102106_bib139","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib140","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","article-title":"Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials","volume":"5","author":"Rivellese","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2025.102106_bib141","series-title":"Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT","author":"Humby","year":"2022"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib142","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/ard.2010.147272","article-title":"Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level","volume":"70","author":"Gutierrez","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2025.102106_bib143","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/rheumatology\/keac479","article-title":"In patients with acute mono\/oligoarthritis, a targeted ultrasound scanning protocol shows great accuracy for the diagnosis of gout and CPPD","volume":"62","author":"Cipolletta","year":"2023","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib144","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1093\/rheumatology\/keu217","article-title":"Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis","volume":"53","author":"Nguyen","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13075-021-02426-w","article-title":"Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission","volume":"23","author":"Terslev","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2025.102106_bib146","article-title":"Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial","volume":"354","author":"Haavardsholm","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.berh.2025.102106_bib147","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/annrheumdis-2015-208941","article-title":"Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial","volume":"75","author":"Dale","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib148","article-title":"Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"Roodenrijs","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2025.102106_bib149","article-title":"Ultrasound response to tofacitinib in patients with rheumatoid arthritis: data from a multicenter 24 weeks prospective study","volume":"9","author":"German\u00f2","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib150","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40744-024-00712-y","article-title":"Clinical and ultrasonographic remission in bio-na\u00efve and bio-failure patients with rheumatoid arthritis at 24 weeks of upadacitinib treatment: the UPARAREMUS real-life study","volume":"11","author":"Picchianti Diamanti","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib151","first-page":"921","article-title":"The role of musculoskeletal ultrasound in predicting the response to JAK inhibitors: results from a monocentric cohort","volume":"40","author":"Ceccarelli","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2025.102106_bib152","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/03009742.2021.1927389","article-title":"Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan","volume":"51","author":"Endo","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2025.102106_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.10.003","article-title":"Systematic review of imaging tests to predict the development of rheumatoid arthritis in people with unclassified arthritis","volume":"52","author":"de Pablo","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib154","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jama.2018.21362","article-title":"Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: the IMAGINE-RA randomized clinical trial","volume":"321","author":"M\u00f8ller-Bisgaard","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-022-02735-8","article-title":"Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept","volume":"24","author":"Ahmad","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2025.102106_bib156","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1409555","article-title":"Advancing precision rheumatology: applications of machine learning for rheumatoid arthritis management","volume":"15","author":"Shi","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.berh.2025.102106_bib157","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00296-025-05825-3","article-title":"Artificial intelligence to predict treatment response in rheumatoid arthritis and spondyloarthritis: a scoping review","volume":"45","author":"Benavent","year":"2025","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.berh.2025.102106_bib158","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaci.2021.08.010","article-title":"The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions","volume":"148","author":"Fragoulis","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2025.102106_bib159","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2025.102106_bib160","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib161","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2025.102106_bib162","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102106_bib163","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib164","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib166","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2025.102106_bib167","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","article-title":"Safety of Janus kinase inhibitors in older patients: a focus on the thromboembolic risk","volume":"37","author":"Rajasimhan","year":"2020","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.berh.2025.102106_bib168","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s13075-014-0435-y","article-title":"A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases","volume":"16","author":"Lee","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib169","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2025.102106_bib170","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2025.102106_bib171","article-title":"MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"9","author":"Charles-Schoeman","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2025.102106_bib173","unstructured":"European Medicines Agency. Janus kinase inhibitors (JAKi)- referral; 2023 Janus kinase inhibitors (JAKi) - referral | European Medicines Agency (EMA); .accessed on 5\/June\/2025."},{"issue":"9","key":"10.1016\/j.berh.2025.102106_bib174","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/art.43188","article-title":"Incidence of Major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries","volume":"77","author":"Aymon","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2025.102106_bib175","first-page":"614","article-title":"Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib176","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1093\/rheumatology\/keac134","article-title":"Comorbidities or extra-articular manifestations: time to reconsider the terminology?","volume":"61","author":"Dey","year":"2022","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib177","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/kez037","article-title":"Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2025.102106_bib178","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1007\/s10067-023-06646-0","article-title":"Prevalence and factors associated with polypharmacy among patients with rheumatoid arthritis: a single-centre, cross-sectional study","volume":"42","author":"Miyake","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2025.102106_bib179","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0897190019869158","article-title":"High levels of polypharmacy in rheumatoid arthritis-a challenge not covered by current management recommendations: data from a large real-life study","volume":"34","author":"Gomides","year":"2021","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.berh.2025.102106_bib180","article-title":"Polypharmacy in middle-European rheumatoid arthritis-patients: a retrospective longitudinal cohort analysis with systematic literature review","volume":"7","author":"Jack","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib181","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13075-023-03191-8","article-title":"Assessing clusters of comorbidities in rheumatoid arthritis: a machine learning approach","volume":"25","author":"Solomon","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib182","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib183","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib184","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102106_bib185","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211002682","article-title":"Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis","volume":"13","author":"Migliore","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102106_bib186","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard-2022-222835","article-title":"After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries","volume":"82","author":"Pombo-Suarez","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib187","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13075-024-03369-8","article-title":"Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry","volume":"26","author":"Ochi","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.berh.2025.102106_bib188","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","article-title":"Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey","volume":"77","author":"Roodenrijs","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2025.102106_bib189","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/rheumatology\/kez222","article-title":"Treatment failure in inflammatory arthritis: time to think about syndemics?","volume":"58","author":"Nikiphorou","year":"2019","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.berh.2025.102106_bib190","first-page":"1472","article-title":"Geographic variation in the quality and cost of care for patients with rheumatoid arthritis","volume":"22","author":"Shafrin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.berh.2025.102106_bib191","doi-asserted-by":"crossref","DOI":"10.1080\/22423982.2023.2166447","article-title":"Disparities in rheumatoid arthritis outcomes for North American Indigenous populations","volume":"78","author":"Hitchon","year":"2019","journal-title":"Int J Circumpolar Health"},{"issue":"11","key":"10.1016\/j.berh.2025.102106_bib192","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","article-title":"Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2025.102106_bib193","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/annrheumdis-2021-220249","article-title":"EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis","volume":"80","author":"Nikiphorou","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T17:13:35Z","timestamp":1765386815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694225000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":189,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1521694225000749"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2025.102106","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary approaches to the management of rheumatoid arthritis: precision and progress","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2025.102106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102106"}}